SiliconInvestor
     Advanced Search   [ sign in ]

sponsor
Sponsor

 Biotech / Medical : Biotech Valuation

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: Miljenko Zuanic who wrote (38128)4/17/2012 10:54:40 AM
From: BiomavenRead Replies (1) of 40274
 
The company argues that this is the first small-molecule VEGF inhibitor that can be combined with other drugs. So they view it long-term as a potential replacement for Avastin - similar tolerability and hopefully more efficacy because it hits all 3 VEGFR receptors.

Peter
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.